P站视频

For epidemic (AIDS-associated) and iatrogenic (transplant related) Kaposi sarcoma (KS), it is most important to treat any immune deficiency that exists, as well as any related infections.

For people with HIV or AIDS, this means using combinations of anti-HIV drugs. This is known as highly active antiretroviral therapy (HAART). For many AIDS patients, HAART may be the only treatment needed to shrink the KS lesions and to keep them under control.

In organ-transplant patients whose immune systems are suppressed by drugs, stopping, lowering or changing the drugs may be helpful. Sirolimus and everolimus are new drugs that may control the KS lesions as well as prevent organ rejection.

New KS lesions are more likely to develop when a patient’s blood test results for Kaposi sarcoma herpesvirus (KSHV) are positive. The risk of developing new lesions is lower when antiviral medicines such as ganciclovir or foscarnet are used. These medicines may help prevent new lesions but they do not help existing lesions get better. They can also cause serious side effects.

KS lesions tend to get worse if you develop bacterial or other active infections. Therefore, it is very important to do what you can to lower your risk of bacterial infections and to treat active infections promptly if they do occur.